nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Respiratory tract infection—Pravastatin—atherosclerosis	0.0158	0.0164	CcSEcCtD
Roflumilast—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.014	0.0146	CcSEcCtD
Roflumilast—Endocrine disorder—Simvastatin—atherosclerosis	0.0133	0.0138	CcSEcCtD
Roflumilast—Gastrooesophageal reflux disease—Ezetimibe—atherosclerosis	0.0128	0.0133	CcSEcCtD
Roflumilast—Gynaecomastia—Rosuvastatin—atherosclerosis	0.0124	0.0129	CcSEcCtD
Roflumilast—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.0121	0.0125	CcSEcCtD
Roflumilast—Renal failure acute—Rosuvastatin—atherosclerosis	0.0109	0.0113	CcSEcCtD
Roflumilast—Gynaecomastia—Lovastatin—atherosclerosis	0.0105	0.0109	CcSEcCtD
Roflumilast—Gynaecomastia—Simvastatin—atherosclerosis	0.00986	0.0102	CcSEcCtD
Roflumilast—Gynaecomastia—Pravastatin—atherosclerosis	0.00891	0.00924	CcSEcCtD
Roflumilast—Influenza—Rosuvastatin—atherosclerosis	0.00872	0.00904	CcSEcCtD
Roflumilast—Atrial fibrillation—Simvastatin—atherosclerosis	0.00844	0.00875	CcSEcCtD
Roflumilast—Renal failure acute—Pravastatin—atherosclerosis	0.00783	0.00812	CcSEcCtD
Roflumilast—Depression—Rosuvastatin—atherosclerosis	0.00775	0.00803	CcSEcCtD
Roflumilast—Atrial fibrillation—Niacin—atherosclerosis	0.00775	0.00803	CcSEcCtD
Roflumilast—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00756	0.00783	CcSEcCtD
Roflumilast—Gastritis—Ezetimibe—atherosclerosis	0.00742	0.00769	CcSEcCtD
Roflumilast—Influenza—Lovastatin—atherosclerosis	0.00739	0.00766	CcSEcCtD
Roflumilast—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00735	0.00762	CcSEcCtD
Roflumilast—Sinusitis—Rosuvastatin—atherosclerosis	0.00729	0.00756	CcSEcCtD
Roflumilast—Influenza—Ezetimibe—atherosclerosis	0.00725	0.00751	CcSEcCtD
Roflumilast—Gastritis—Simvastatin—atherosclerosis	0.00708	0.00733	CcSEcCtD
Roflumilast—Rhinitis—Rosuvastatin—atherosclerosis	0.007	0.00725	CcSEcCtD
Roflumilast—Infestation NOS—Ezetimibe—atherosclerosis	0.00646	0.0067	CcSEcCtD
Roflumilast—Infestation—Ezetimibe—atherosclerosis	0.00646	0.0067	CcSEcCtD
Roflumilast—Urinary tract infection—Lovastatin—atherosclerosis	0.0064	0.00664	CcSEcCtD
Roflumilast—Influenza—Niacin—atherosclerosis	0.00635	0.00658	CcSEcCtD
Roflumilast—Influenza—Pravastatin—atherosclerosis	0.00625	0.00648	CcSEcCtD
Roflumilast—Sinusitis—Lovastatin—atherosclerosis	0.00618	0.00641	CcSEcCtD
Roflumilast—Depression—Simvastatin—atherosclerosis	0.00615	0.00637	CcSEcCtD
Roflumilast—Mental disorder—Rosuvastatin—atherosclerosis	0.00612	0.00634	CcSEcCtD
Roflumilast—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00611	0.00633	CcSEcCtD
Roflumilast—Sinusitis—Ezetimibe—atherosclerosis	0.00606	0.00628	CcSEcCtD
Roflumilast—Sinusitis—Simvastatin—atherosclerosis	0.00578	0.00599	CcSEcCtD
Roflumilast—Connective tissue disorder—Ezetimibe—atherosclerosis	0.0057	0.00591	CcSEcCtD
Roflumilast—Weight decreased—Pravastatin—atherosclerosis	0.00565	0.00586	CcSEcCtD
Roflumilast—Depression—Pravastatin—atherosclerosis	0.00556	0.00576	CcSEcCtD
Roflumilast—Angioedema—Rosuvastatin—atherosclerosis	0.00555	0.00575	CcSEcCtD
Roflumilast—Urinary tract infection—Pravastatin—atherosclerosis	0.00542	0.00561	CcSEcCtD
Roflumilast—Immune system disorder—Ezetimibe—atherosclerosis	0.00524	0.00543	CcSEcCtD
Roflumilast—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00523	0.00542	CcSEcCtD
Roflumilast—Sinusitis—Pravastatin—atherosclerosis	0.00523	0.00542	CcSEcCtD
Roflumilast—Myalgia—Rosuvastatin—atherosclerosis	0.00517	0.00536	CcSEcCtD
Roflumilast—Rhinitis—Niacin—atherosclerosis	0.00509	0.00528	CcSEcCtD
Roflumilast—Mental disorder—Ezetimibe—atherosclerosis	0.00508	0.00527	CcSEcCtD
Roflumilast—Malnutrition—Ezetimibe—atherosclerosis	0.00505	0.00523	CcSEcCtD
Roflumilast—Dysgeusia—Lovastatin—atherosclerosis	0.00504	0.00523	CcSEcCtD
Roflumilast—Rhinitis—Pravastatin—atherosclerosis	0.00501	0.0052	CcSEcCtD
Roflumilast—Back pain—Lovastatin—atherosclerosis	0.00498	0.00516	CcSEcCtD
Roflumilast—Muscle spasms—Lovastatin—atherosclerosis	0.00495	0.00513	CcSEcCtD
Roflumilast—Infection—Rosuvastatin—atherosclerosis	0.00493	0.00511	CcSEcCtD
Roflumilast—Back pain—Ezetimibe—atherosclerosis	0.00489	0.00506	CcSEcCtD
Roflumilast—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00486	0.00504	CcSEcCtD
Roflumilast—Muscle spasms—Ezetimibe—atherosclerosis	0.00486	0.00503	CcSEcCtD
Roflumilast—Mental disorder—Simvastatin—atherosclerosis	0.00485	0.00502	CcSEcCtD
Roflumilast—Tremor—Lovastatin—atherosclerosis	0.00482	0.005	CcSEcCtD
Roflumilast—Ill-defined disorder—Lovastatin—atherosclerosis	0.00478	0.00495	CcSEcCtD
Roflumilast—Dysgeusia—Simvastatin—atherosclerosis	0.00472	0.00489	CcSEcCtD
Roflumilast—Angioedema—Lovastatin—atherosclerosis	0.00471	0.00488	CcSEcCtD
Roflumilast—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00469	0.00486	CcSEcCtD
Roflumilast—Malaise—Lovastatin—atherosclerosis	0.00464	0.00481	CcSEcCtD
Roflumilast—Cardiac disorder—Pravastatin—atherosclerosis	0.00464	0.00481	CcSEcCtD
Roflumilast—Muscle spasms—Simvastatin—atherosclerosis	0.00463	0.0048	CcSEcCtD
Roflumilast—Vertigo—Lovastatin—atherosclerosis	0.00463	0.00479	CcSEcCtD
Roflumilast—Angioedema—Ezetimibe—atherosclerosis	0.00461	0.00478	CcSEcCtD
Roflumilast—Malaise—Ezetimibe—atherosclerosis	0.00455	0.00472	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00452	0.00468	CcSEcCtD
Roflumilast—Tremor—Simvastatin—atherosclerosis	0.00451	0.00468	CcSEcCtD
Roflumilast—Insomnia—Rosuvastatin—atherosclerosis	0.00449	0.00465	CcSEcCtD
Roflumilast—Ill-defined disorder—Simvastatin—atherosclerosis	0.00447	0.00463	CcSEcCtD
Roflumilast—Palpitations—Ezetimibe—atherosclerosis	0.00446	0.00463	CcSEcCtD
Roflumilast—Malnutrition—Niacin—atherosclerosis	0.00442	0.00458	CcSEcCtD
Roflumilast—Angioedema—Simvastatin—atherosclerosis	0.0044	0.00456	CcSEcCtD
Roflumilast—Myalgia—Lovastatin—atherosclerosis	0.00438	0.00454	CcSEcCtD
Roflumilast—Anxiety—Lovastatin—atherosclerosis	0.00437	0.00453	CcSEcCtD
Roflumilast—Dyspepsia—Rosuvastatin—atherosclerosis	0.00437	0.00452	CcSEcCtD
Roflumilast—Malaise—Simvastatin—atherosclerosis	0.00434	0.0045	CcSEcCtD
Roflumilast—Tension—Niacin—atherosclerosis	0.00434	0.0045	CcSEcCtD
Roflumilast—Discomfort—Lovastatin—atherosclerosis	0.00433	0.00449	CcSEcCtD
Roflumilast—Vertigo—Simvastatin—atherosclerosis	0.00433	0.00448	CcSEcCtD
Roflumilast—Myalgia—Ezetimibe—atherosclerosis	0.0043	0.00446	CcSEcCtD
Roflumilast—Nervousness—Niacin—atherosclerosis	0.0043	0.00445	CcSEcCtD
Roflumilast—Tension—Pravastatin—atherosclerosis	0.00427	0.00443	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00427	0.00443	CcSEcCtD
Roflumilast—Dysgeusia—Pravastatin—atherosclerosis	0.00426	0.00442	CcSEcCtD
Roflumilast—Muscle spasms—Niacin—atherosclerosis	0.00425	0.00441	CcSEcCtD
Roflumilast—Discomfort—Ezetimibe—atherosclerosis	0.00425	0.0044	CcSEcCtD
Roflumilast—Constipation—Rosuvastatin—atherosclerosis	0.00424	0.00439	CcSEcCtD
Roflumilast—Nervousness—Pravastatin—atherosclerosis	0.00423	0.00438	CcSEcCtD
Roflumilast—Muscle spasms—Pravastatin—atherosclerosis	0.00419	0.00434	CcSEcCtD
Roflumilast—Infection—Lovastatin—atherosclerosis	0.00418	0.00433	CcSEcCtD
Roflumilast—Myalgia—Simvastatin—atherosclerosis	0.0041	0.00425	CcSEcCtD
Roflumilast—Infection—Ezetimibe—atherosclerosis	0.0041	0.00424	CcSEcCtD
Roflumilast—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00409	0.00423	CcSEcCtD
Roflumilast—Anxiety—Simvastatin—atherosclerosis	0.00409	0.00423	CcSEcCtD
Roflumilast—Tremor—Pravastatin—atherosclerosis	0.00408	0.00423	CcSEcCtD
Roflumilast—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00406	0.0042	CcSEcCtD
Roflumilast—Discomfort—Simvastatin—atherosclerosis	0.00405	0.0042	CcSEcCtD
Roflumilast—Nervous system disorder—Ezetimibe—atherosclerosis	0.00404	0.00419	CcSEcCtD
Roflumilast—Angioedema—Niacin—atherosclerosis	0.00404	0.00419	CcSEcCtD
Roflumilast—Ill-defined disorder—Pravastatin—atherosclerosis	0.00404	0.00419	CcSEcCtD
Roflumilast—Skin disorder—Ezetimibe—atherosclerosis	0.004	0.00415	CcSEcCtD
Roflumilast—Angioedema—Pravastatin—atherosclerosis	0.00398	0.00412	CcSEcCtD
Roflumilast—Vertigo—Niacin—atherosclerosis	0.00397	0.00412	CcSEcCtD
Roflumilast—Urticaria—Rosuvastatin—atherosclerosis	0.00394	0.00408	CcSEcCtD
Roflumilast—Malaise—Pravastatin—atherosclerosis	0.00393	0.00407	CcSEcCtD
Roflumilast—Abdominal pain—Rosuvastatin—atherosclerosis	0.00392	0.00406	CcSEcCtD
Roflumilast—Vertigo—Pravastatin—atherosclerosis	0.00391	0.00405	CcSEcCtD
Roflumilast—Palpitations—Niacin—atherosclerosis	0.00391	0.00405	CcSEcCtD
Roflumilast—Infection—Simvastatin—atherosclerosis	0.00391	0.00405	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00383	0.00397	CcSEcCtD
Roflumilast—Insomnia—Lovastatin—atherosclerosis	0.0038	0.00394	CcSEcCtD
Roflumilast—Myalgia—Niacin—atherosclerosis	0.00377	0.0039	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00376	0.00389	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00374	0.00387	CcSEcCtD
Roflumilast—Insomnia—Ezetimibe—atherosclerosis	0.00373	0.00386	CcSEcCtD
Roflumilast—Myalgia—Pravastatin—atherosclerosis	0.00371	0.00384	CcSEcCtD
Roflumilast—Dyspepsia—Lovastatin—atherosclerosis	0.0037	0.00383	CcSEcCtD
Roflumilast—Anxiety—Pravastatin—atherosclerosis	0.00369	0.00383	CcSEcCtD
Roflumilast—Discomfort—Pravastatin—atherosclerosis	0.00366	0.0038	CcSEcCtD
Roflumilast—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00365	0.00379	CcSEcCtD
Roflumilast—Decreased appetite—Lovastatin—atherosclerosis	0.00365	0.00379	CcSEcCtD
Roflumilast—Dyspepsia—Ezetimibe—atherosclerosis	0.00363	0.00376	CcSEcCtD
Roflumilast—Fatigue—Lovastatin—atherosclerosis	0.00362	0.00375	CcSEcCtD
Roflumilast—Constipation—Lovastatin—atherosclerosis	0.00359	0.00372	CcSEcCtD
Roflumilast—Decreased appetite—Ezetimibe—atherosclerosis	0.00358	0.00371	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00358	0.00371	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00356	0.00369	CcSEcCtD
Roflumilast—Asthenia—Rosuvastatin—atherosclerosis	0.00356	0.00369	CcSEcCtD
Roflumilast—Insomnia—Simvastatin—atherosclerosis	0.00356	0.00368	CcSEcCtD
Roflumilast—Fatigue—Ezetimibe—atherosclerosis	0.00355	0.00368	CcSEcCtD
Roflumilast—Infection—Pravastatin—atherosclerosis	0.00353	0.00366	CcSEcCtD
Roflumilast—Constipation—Ezetimibe—atherosclerosis	0.00352	0.00365	CcSEcCtD
Roflumilast—Skin disorder—Niacin—atherosclerosis	0.00351	0.00363	CcSEcCtD
Roflumilast—Feeling abnormal—Lovastatin—atherosclerosis	0.00346	0.00359	CcSEcCtD
Roflumilast—Dyspepsia—Simvastatin—atherosclerosis	0.00346	0.00359	CcSEcCtD
Roflumilast—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00344	0.00356	CcSEcCtD
Roflumilast—Decreased appetite—Simvastatin—atherosclerosis	0.00342	0.00354	CcSEcCtD
Roflumilast—Feeling abnormal—Ezetimibe—atherosclerosis	0.0034	0.00352	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00339	0.00352	CcSEcCtD
Roflumilast—Diarrhoea—Rosuvastatin—atherosclerosis	0.00339	0.00352	CcSEcCtD
Roflumilast—Fatigue—Simvastatin—atherosclerosis	0.00339	0.00351	CcSEcCtD
Roflumilast—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00337	0.00349	CcSEcCtD
Roflumilast—Constipation—Simvastatin—atherosclerosis	0.00336	0.00348	CcSEcCtD
Roflumilast—Urticaria—Lovastatin—atherosclerosis	0.00334	0.00346	CcSEcCtD
Roflumilast—Abdominal pain—Lovastatin—atherosclerosis	0.00332	0.00344	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00329	0.00341	CcSEcCtD
Roflumilast—Dizziness—Rosuvastatin—atherosclerosis	0.00328	0.0034	CcSEcCtD
Roflumilast—Urticaria—Ezetimibe—atherosclerosis	0.00327	0.00339	CcSEcCtD
Roflumilast—Insomnia—Niacin—atherosclerosis	0.00326	0.00338	CcSEcCtD
Roflumilast—Abdominal pain—Ezetimibe—atherosclerosis	0.00326	0.00338	CcSEcCtD
Roflumilast—Feeling abnormal—Simvastatin—atherosclerosis	0.00324	0.00336	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00324	0.00336	CcSEcCtD
Roflumilast—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00321	0.00333	CcSEcCtD
Roflumilast—Insomnia—Pravastatin—atherosclerosis	0.00321	0.00333	CcSEcCtD
Roflumilast—Dyspepsia—Niacin—atherosclerosis	0.00318	0.00329	CcSEcCtD
Roflumilast—Decreased appetite—Niacin—atherosclerosis	0.00314	0.00325	CcSEcCtD
Roflumilast—Dyspepsia—Pravastatin—atherosclerosis	0.00313	0.00324	CcSEcCtD
Roflumilast—Rash—Rosuvastatin—atherosclerosis	0.00313	0.00324	CcSEcCtD
Roflumilast—Dermatitis—Rosuvastatin—atherosclerosis	0.00312	0.00324	CcSEcCtD
Roflumilast—Urticaria—Simvastatin—atherosclerosis	0.00312	0.00324	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Niacin—atherosclerosis	0.00312	0.00323	CcSEcCtD
Roflumilast—Abdominal pain—Simvastatin—atherosclerosis	0.00311	0.00322	CcSEcCtD
Roflumilast—Headache—Rosuvastatin—atherosclerosis	0.00311	0.00322	CcSEcCtD
Roflumilast—Hypersensitivity—Lovastatin—atherosclerosis	0.0031	0.00321	CcSEcCtD
Roflumilast—Decreased appetite—Pravastatin—atherosclerosis	0.00309	0.0032	CcSEcCtD
Roflumilast—Fatigue—Pravastatin—atherosclerosis	0.00306	0.00318	CcSEcCtD
Roflumilast—Constipation—Pravastatin—atherosclerosis	0.00304	0.00315	CcSEcCtD
Roflumilast—Hypersensitivity—Ezetimibe—atherosclerosis	0.00304	0.00315	CcSEcCtD
Roflumilast—Asthenia—Lovastatin—atherosclerosis	0.00302	0.00312	CcSEcCtD
Roflumilast—Asthenia—Ezetimibe—atherosclerosis	0.00296	0.00306	CcSEcCtD
Roflumilast—Gastrointestinal pain—Niacin—atherosclerosis	0.00295	0.00306	CcSEcCtD
Roflumilast—Nausea—Rosuvastatin—atherosclerosis	0.00295	0.00305	CcSEcCtD
Roflumilast—Feeling abnormal—Pravastatin—atherosclerosis	0.00293	0.00303	CcSEcCtD
Roflumilast—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00291	0.00301	CcSEcCtD
Roflumilast—Hypersensitivity—Simvastatin—atherosclerosis	0.0029	0.003	CcSEcCtD
Roflumilast—Diarrhoea—Lovastatin—atherosclerosis	0.00288	0.00298	CcSEcCtD
Roflumilast—Urticaria—Niacin—atherosclerosis	0.00287	0.00297	CcSEcCtD
Roflumilast—Abdominal pain—Niacin—atherosclerosis	0.00285	0.00296	CcSEcCtD
Roflumilast—Urticaria—Pravastatin—atherosclerosis	0.00282	0.00293	CcSEcCtD
Roflumilast—Asthenia—Simvastatin—atherosclerosis	0.00282	0.00292	CcSEcCtD
Roflumilast—Diarrhoea—Ezetimibe—atherosclerosis	0.00282	0.00292	CcSEcCtD
Roflumilast—Abdominal pain—Pravastatin—atherosclerosis	0.00281	0.00291	CcSEcCtD
Roflumilast—Dizziness—Lovastatin—atherosclerosis	0.00278	0.00288	CcSEcCtD
Roflumilast—Dizziness—Ezetimibe—atherosclerosis	0.00273	0.00282	CcSEcCtD
Roflumilast—Diarrhoea—Simvastatin—atherosclerosis	0.00269	0.00279	CcSEcCtD
Roflumilast—Vomiting—Lovastatin—atherosclerosis	0.00267	0.00277	CcSEcCtD
Roflumilast—Hypersensitivity—Niacin—atherosclerosis	0.00266	0.00276	CcSEcCtD
Roflumilast—Rash—Lovastatin—atherosclerosis	0.00265	0.00275	CcSEcCtD
Roflumilast—Dermatitis—Lovastatin—atherosclerosis	0.00265	0.00274	CcSEcCtD
Roflumilast—Headache—Lovastatin—atherosclerosis	0.00263	0.00273	CcSEcCtD
Roflumilast—Vomiting—Ezetimibe—atherosclerosis	0.00262	0.00272	CcSEcCtD
Roflumilast—Hypersensitivity—Pravastatin—atherosclerosis	0.00262	0.00271	CcSEcCtD
Roflumilast—Dizziness—Simvastatin—atherosclerosis	0.0026	0.00269	CcSEcCtD
Roflumilast—Rash—Ezetimibe—atherosclerosis	0.0026	0.00269	CcSEcCtD
Roflumilast—Dermatitis—Ezetimibe—atherosclerosis	0.0026	0.00269	CcSEcCtD
Roflumilast—Asthenia—Niacin—atherosclerosis	0.00259	0.00268	CcSEcCtD
Roflumilast—Headache—Ezetimibe—atherosclerosis	0.00258	0.00268	CcSEcCtD
Roflumilast—Asthenia—Pravastatin—atherosclerosis	0.00255	0.00264	CcSEcCtD
Roflumilast—Vomiting—Simvastatin—atherosclerosis	0.0025	0.00259	CcSEcCtD
Roflumilast—Nausea—Lovastatin—atherosclerosis	0.0025	0.00259	CcSEcCtD
Roflumilast—Rash—Simvastatin—atherosclerosis	0.00248	0.00257	CcSEcCtD
Roflumilast—Dermatitis—Simvastatin—atherosclerosis	0.00248	0.00257	CcSEcCtD
Roflumilast—Diarrhoea—Niacin—atherosclerosis	0.00247	0.00256	CcSEcCtD
Roflumilast—Headache—Simvastatin—atherosclerosis	0.00246	0.00255	CcSEcCtD
Roflumilast—Nausea—Ezetimibe—atherosclerosis	0.00245	0.00254	CcSEcCtD
Roflumilast—Diarrhoea—Pravastatin—atherosclerosis	0.00243	0.00252	CcSEcCtD
Roflumilast—Dizziness—Niacin—atherosclerosis	0.00239	0.00247	CcSEcCtD
Roflumilast—Dizziness—Pravastatin—atherosclerosis	0.00235	0.00244	CcSEcCtD
Roflumilast—Nausea—Simvastatin—atherosclerosis	0.00233	0.00242	CcSEcCtD
Roflumilast—Vomiting—Niacin—atherosclerosis	0.00229	0.00238	CcSEcCtD
Roflumilast—Rash—Niacin—atherosclerosis	0.00228	0.00236	CcSEcCtD
Roflumilast—Dermatitis—Niacin—atherosclerosis	0.00227	0.00236	CcSEcCtD
Roflumilast—Headache—Niacin—atherosclerosis	0.00226	0.00234	CcSEcCtD
Roflumilast—Vomiting—Pravastatin—atherosclerosis	0.00226	0.00234	CcSEcCtD
Roflumilast—Rash—Pravastatin—atherosclerosis	0.00224	0.00232	CcSEcCtD
Roflumilast—Dermatitis—Pravastatin—atherosclerosis	0.00224	0.00232	CcSEcCtD
Roflumilast—Headache—Pravastatin—atherosclerosis	0.00223	0.00231	CcSEcCtD
Roflumilast—Nausea—Niacin—atherosclerosis	0.00214	0.00222	CcSEcCtD
Roflumilast—Nausea—Pravastatin—atherosclerosis	0.00211	0.00219	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—NCF1—atherosclerosis	7.68e-05	0.00219	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCL5—atherosclerosis	7.64e-05	0.00218	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PRKCG—atherosclerosis	7.62e-05	0.00218	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CX3CL1—atherosclerosis	7.54e-05	0.00216	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—F2—atherosclerosis	7.47e-05	0.00214	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—EDN1—atherosclerosis	7.47e-05	0.00214	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CCL5—atherosclerosis	7.41e-05	0.00212	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AGT—atherosclerosis	7.35e-05	0.0021	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EDN1—atherosclerosis	7.33e-05	0.0021	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCL5—atherosclerosis	7.28e-05	0.00208	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PRKCG—atherosclerosis	7.27e-05	0.00208	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCR2—atherosclerosis	7.25e-05	0.00207	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EDNRA—atherosclerosis	7.25e-05	0.00207	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VWF—atherosclerosis	7.24e-05	0.00207	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CYBA—atherosclerosis	7.22e-05	0.00206	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOC3—atherosclerosis	7.19e-05	0.00206	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CG—atherosclerosis	7.15e-05	0.00204	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CNR2—atherosclerosis	7.15e-05	0.00204	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LDLR—atherosclerosis	7.15e-05	0.00204	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MMP3—atherosclerosis	7.13e-05	0.00204	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PARP1—atherosclerosis	7.07e-05	0.00202	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PLAT—atherosclerosis	7.07e-05	0.00202	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GHRL—atherosclerosis	7.07e-05	0.00202	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PRKCG—atherosclerosis	7.05e-05	0.00201	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AGT—atherosclerosis	7.04e-05	0.00201	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL3—atherosclerosis	6.98e-05	0.002	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PRKCG—atherosclerosis	6.92e-05	0.00198	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VWF—atherosclerosis	6.89e-05	0.00197	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOC3—atherosclerosis	6.84e-05	0.00196	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LDLR—atherosclerosis	6.8e-05	0.00194	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—F2—atherosclerosis	6.79e-05	0.00194	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EDN1—atherosclerosis	6.78e-05	0.00194	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCL5—atherosclerosis	6.73e-05	0.00192	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AGT—atherosclerosis	6.7e-05	0.00192	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NCF1—atherosclerosis	6.68e-05	0.00191	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL3—atherosclerosis	6.64e-05	0.0019	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—F2—atherosclerosis	6.51e-05	0.00186	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CG—atherosclerosis	6.5e-05	0.00186	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PRKCG—atherosclerosis	6.4e-05	0.00183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AGT—atherosclerosis	6.39e-05	0.00183	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VWF—atherosclerosis	6.37e-05	0.00182	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NCF1—atherosclerosis	6.36e-05	0.00182	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOC3—atherosclerosis	6.33e-05	0.00181	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCR2—atherosclerosis	6.31e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EDNRA—atherosclerosis	6.31e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LDLR—atherosclerosis	6.29e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CYBA—atherosclerosis	6.29e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CG—atherosclerosis	6.23e-05	0.00178	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KNG1—atherosclerosis	6.2e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AGT—atherosclerosis	6.2e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—F2—atherosclerosis	6.19e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AGTR1—atherosclerosis	6.17e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PARP1—atherosclerosis	6.15e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GHRL—atherosclerosis	6.15e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PLAT—atherosclerosis	6.15e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL3—atherosclerosis	6.15e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AGT—atherosclerosis	6.09e-05	0.00174	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCL2—atherosclerosis	6.05e-05	0.00173	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCR2—atherosclerosis	6.01e-05	0.00172	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EDNRA—atherosclerosis	6.01e-05	0.00172	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PLG—atherosclerosis	6.01e-05	0.00172	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CYBA—atherosclerosis	5.98e-05	0.00171	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CG—atherosclerosis	5.93e-05	0.00169	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—F2—atherosclerosis	5.91e-05	0.00169	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NCF1—atherosclerosis	5.89e-05	0.00168	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PARP1—atherosclerosis	5.86e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PLAT—atherosclerosis	5.86e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GHRL—atherosclerosis	5.86e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—F2—atherosclerosis	5.73e-05	0.00164	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SOCS3—atherosclerosis	5.69e-05	0.00163	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CG—atherosclerosis	5.65e-05	0.00162	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AGT—atherosclerosis	5.63e-05	0.00161	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—F2—atherosclerosis	5.62e-05	0.00161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EDNRA—atherosclerosis	5.56e-05	0.00159	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCR2—atherosclerosis	5.56e-05	0.00159	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CYBA—atherosclerosis	5.54e-05	0.00158	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP3—atherosclerosis	5.5e-05	0.00157	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CG—atherosclerosis	5.48e-05	0.00157	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF2—atherosclerosis	5.47e-05	0.00156	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PLAT—atherosclerosis	5.42e-05	0.00155	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PARP1—atherosclerosis	5.42e-05	0.00155	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GHRL—atherosclerosis	5.42e-05	0.00155	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KNG1—atherosclerosis	5.4e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CG—atherosclerosis	5.38e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AGTR1—atherosclerosis	5.37e-05	0.00153	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOB—atherosclerosis	5.31e-05	0.00152	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCL8—atherosclerosis	5.27e-05	0.00151	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCL2—atherosclerosis	5.27e-05	0.00151	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PLG—atherosclerosis	5.23e-05	0.0015	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EDN1—atherosclerosis	5.23e-05	0.00149	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—F2—atherosclerosis	5.2e-05	0.00149	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL5—atherosclerosis	5.19e-05	0.00148	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KNG1—atherosclerosis	5.14e-05	0.00147	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AGTR1—atherosclerosis	5.11e-05	0.00146	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LPL—atherosclerosis	5.07e-05	0.00145	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCL2—atherosclerosis	5.01e-05	0.00143	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CG—atherosclerosis	4.98e-05	0.00142	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PLG—atherosclerosis	4.98e-05	0.00142	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SOCS3—atherosclerosis	4.95e-05	0.00142	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PRKCG—atherosclerosis	4.93e-05	0.00141	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SPP1—atherosclerosis	4.8e-05	0.00137	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP3—atherosclerosis	4.78e-05	0.00137	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CXCL8—atherosclerosis	4.78e-05	0.00137	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF2—atherosclerosis	4.76e-05	0.00136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KNG1—atherosclerosis	4.76e-05	0.00136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AGTR1—atherosclerosis	4.73e-05	0.00135	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SOCS3—atherosclerosis	4.72e-05	0.00135	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCL2—atherosclerosis	4.64e-05	0.00133	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOB—atherosclerosis	4.62e-05	0.00132	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PLG—atherosclerosis	4.61e-05	0.00132	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CXCL8—atherosclerosis	4.58e-05	0.00131	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP3—atherosclerosis	4.55e-05	0.0013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EDN1—atherosclerosis	4.55e-05	0.0013	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF2—atherosclerosis	4.53e-05	0.0013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL5—atherosclerosis	4.52e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PDGFB—atherosclerosis	4.44e-05	0.00127	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LPL—atherosclerosis	4.42e-05	0.00126	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOB—atherosclerosis	4.4e-05	0.00126	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL8—atherosclerosis	4.36e-05	0.00125	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SOCS3—atherosclerosis	4.36e-05	0.00125	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AGT—atherosclerosis	4.34e-05	0.00124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EDN1—atherosclerosis	4.33e-05	0.00124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL5—atherosclerosis	4.3e-05	0.00123	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PRKCG—atherosclerosis	4.29e-05	0.00123	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LEP—atherosclerosis	4.25e-05	0.00122	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOE—atherosclerosis	4.25e-05	0.00122	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP3—atherosclerosis	4.21e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CAV1—atherosclerosis	4.21e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LPL—atherosclerosis	4.2e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOA1—atherosclerosis	4.2e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF2—atherosclerosis	4.2e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SPP1—atherosclerosis	4.18e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL8—atherosclerosis	4.16e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PRKCG—atherosclerosis	4.09e-05	0.00117	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOB—atherosclerosis	4.07e-05	0.00116	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ESR1—atherosclerosis	4.06e-05	0.00116	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL8—atherosclerosis	4.04e-05	0.00115	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—F2—atherosclerosis	4.01e-05	0.00115	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EDN1—atherosclerosis	4.01e-05	0.00115	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SPP1—atherosclerosis	3.98e-05	0.00114	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL5—atherosclerosis	3.98e-05	0.00114	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL8—atherosclerosis	3.96e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LPL—atherosclerosis	3.89e-05	0.00111	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PDGFB—atherosclerosis	3.87e-05	0.00111	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CG—atherosclerosis	3.84e-05	0.0011	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PRKCG—atherosclerosis	3.78e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AGT—atherosclerosis	3.78e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LEP—atherosclerosis	3.7e-05	0.00106	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOE—atherosclerosis	3.7e-05	0.00106	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PDGFB—atherosclerosis	3.68e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SPP1—atherosclerosis	3.68e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK3—atherosclerosis	3.67e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CAV1—atherosclerosis	3.67e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL8—atherosclerosis	3.67e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOA1—atherosclerosis	3.66e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—INS—atherosclerosis	3.63e-05	0.00104	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AGT—atherosclerosis	3.6e-05	0.00103	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL2—atherosclerosis	3.57e-05	0.00102	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ESR1—atherosclerosis	3.53e-05	0.00101	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOE—atherosclerosis	3.52e-05	0.00101	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LEP—atherosclerosis	3.52e-05	0.00101	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1—atherosclerosis	3.51e-05	0.001	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CAV1—atherosclerosis	3.49e-05	0.000998	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—F2—atherosclerosis	3.49e-05	0.000998	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOA1—atherosclerosis	3.48e-05	0.000995	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDGFB—atherosclerosis	3.41e-05	0.000974	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ESR1—atherosclerosis	3.36e-05	0.000961	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CG—atherosclerosis	3.34e-05	0.000955	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SERPINE1—atherosclerosis	3.34e-05	0.000954	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AGT—atherosclerosis	3.33e-05	0.000951	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—F2—atherosclerosis	3.32e-05	0.00095	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LEP—atherosclerosis	3.26e-05	0.000932	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOE—atherosclerosis	3.26e-05	0.000932	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CAV1—atherosclerosis	3.23e-05	0.000923	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOA1—atherosclerosis	3.22e-05	0.000921	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK3—atherosclerosis	3.2e-05	0.000914	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOS3—atherosclerosis	3.19e-05	0.00091	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CG—atherosclerosis	3.18e-05	0.000909	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—INS—atherosclerosis	3.16e-05	0.000904	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ESR1—atherosclerosis	3.11e-05	0.00089	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL2—atherosclerosis	3.11e-05	0.000889	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—F2—atherosclerosis	3.07e-05	0.000879	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1—atherosclerosis	3.06e-05	0.000874	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK3—atherosclerosis	3.04e-05	0.00087	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—INS—atherosclerosis	3.01e-05	0.00086	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL2—atherosclerosis	2.96e-05	0.000846	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CG—atherosclerosis	2.94e-05	0.000841	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1—atherosclerosis	2.91e-05	0.000832	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SERPINE1—atherosclerosis	2.9e-05	0.00083	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL8—atherosclerosis	2.83e-05	0.000808	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK3—atherosclerosis	2.82e-05	0.000805	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—INS—atherosclerosis	2.78e-05	0.000796	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOS3—atherosclerosis	2.77e-05	0.000793	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SERPINE1—atherosclerosis	2.76e-05	0.00079	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL2—atherosclerosis	2.74e-05	0.000783	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—AKT1—atherosclerosis	2.73e-05	0.00078	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1—atherosclerosis	2.69e-05	0.00077	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—atherosclerosis	2.69e-05	0.000768	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOS3—atherosclerosis	2.64e-05	0.000754	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SERPINE1—atherosclerosis	2.56e-05	0.000731	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—atherosclerosis	2.56e-05	0.00073	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NFKB1—atherosclerosis	2.53e-05	0.000723	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK8—atherosclerosis	2.49e-05	0.00071	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT1—atherosclerosis	2.48e-05	0.000708	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL8—atherosclerosis	2.46e-05	0.000703	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOS3—atherosclerosis	2.44e-05	0.000698	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT1—atherosclerosis	2.38e-05	0.000679	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL8—atherosclerosis	2.34e-05	0.000669	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—atherosclerosis	2.34e-05	0.000669	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—atherosclerosis	2.29e-05	0.000656	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—STAT3—atherosclerosis	2.27e-05	0.000649	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT1—atherosclerosis	2.26e-05	0.000646	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—atherosclerosis	2.23e-05	0.000636	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—atherosclerosis	2.22e-05	0.000636	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NFKB1—atherosclerosis	2.2e-05	0.000629	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK3—atherosclerosis	2.17e-05	0.00062	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL8—atherosclerosis	2.17e-05	0.000619	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK8—atherosclerosis	2.16e-05	0.000618	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT1—atherosclerosis	2.16e-05	0.000617	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—atherosclerosis	2.12e-05	0.000605	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—atherosclerosis	2.11e-05	0.000602	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NFKB1—atherosclerosis	2.1e-05	0.000599	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT1—atherosclerosis	2.09e-05	0.000598	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—atherosclerosis	2.06e-05	0.000589	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK8—atherosclerosis	2.06e-05	0.000589	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT1—atherosclerosis	2.05e-05	0.000587	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—atherosclerosis	2e-05	0.000571	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—STAT3—atherosclerosis	1.98e-05	0.000565	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—atherosclerosis	1.96e-05	0.00056	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NFKB1—atherosclerosis	1.94e-05	0.000554	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK8—atherosclerosis	1.91e-05	0.000545	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—atherosclerosis	1.9e-05	0.000543	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT1—atherosclerosis	1.9e-05	0.000543	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK3—atherosclerosis	1.89e-05	0.00054	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—STAT3—atherosclerosis	1.88e-05	0.000538	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—atherosclerosis	1.83e-05	0.000524	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK3—atherosclerosis	1.8e-05	0.000514	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—atherosclerosis	1.76e-05	0.000503	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—atherosclerosis	1.75e-05	0.000499	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—STAT3—atherosclerosis	1.74e-05	0.000498	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK3—atherosclerosis	1.66e-05	0.000476	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—atherosclerosis	1.61e-05	0.000462	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—atherosclerosis	1.59e-05	0.000454	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT1—atherosclerosis	1.46e-05	0.000419	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—atherosclerosis	1.38e-05	0.000395	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—atherosclerosis	1.32e-05	0.000376	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT1—atherosclerosis	1.27e-05	0.000364	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—atherosclerosis	1.22e-05	0.000348	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT1—atherosclerosis	1.21e-05	0.000347	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT1—atherosclerosis	1.12e-05	0.000321	CbGpPWpGaD
